MAXIGEN BIOTECH INC.

Q2 2021 Investor Conference

AGENDA

1. Opening Remarks — Mandy Huang
2. Q2 2021 Financial Review — Grace Yu
3. Q&A — Sung-Ching Chen, Po-Hong Lai, Grace Yu, Mandy Huang

SAFE HARBOR NOTICE

TCI's statements of its current expectations are forwardlooking statements subject to significant risks and uncertainties and actual results may differ materially from those contained in the forward-looking statements.
Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

The Collagen & HA Biotech Company

Stock 1783 TT
Employee 150
Revenue in 2020 NTD 458 Million

1998
Established in 1998

2002
Establish the medical device & cosmetic Dep.

2006
Certified by US FDA on medical consumables/device

2013
Listed in TWSE

2017
The medical consumables/device was certified in Indonesia

IND

2018
The medical consumables/device was certified in Russia, Malaysia, and Taiwan

RUS
MY
TW

2019
The medical consumables/device was certified in Europe

July 2021
TCI Co., Ltd became the largest shareholder, and Mr. Vincent Lin has been elected as the Chairman

Formosa Biomedical Technology Corp. to invest via private placement

Developing Future

The Global Footprint



Dedicated to the Biotech Application with Collagen & HA

Sales Breakdown
– by Product



Sales Breakdown By Region



Certified Medical Device Factory

Passed the FDA Audit with 0 failure

GMP CERTIFIED

GMP

ISO 13485:2016

FDA

KFDA

Korea Food & Drug Administration

식품의약품안전청

FDA

Certified Cosmetics Factory

2021
Financial Review

Q2 2021 Consolidated Financial Report

(TWD'Million)

	Q2 2021 Amount	%	Q1 2021 Amount	%	QoQ %	Q2 2020 Amount	%	YoY %
Operating Revenue	121	100%	111	100%	9%	116	100%	4%
Gross Margin	63	52%	60	54%	5%	53	46%	19%
Operating Expenses	(42)	-35%	(38)	-34%	11%	(38)	-33%	11%
- Selling	(11)	-9%	(8)	-7%	38%	(8)	-7%	38%
- G&A	(12)	-10%	(14)	-13%	-14%	(13)	-11%	-8%
- R&D	(19)	-16%	(16)	-14%	19%	(17)	-15%	12%
- Expected Credit Losses	0	0%	0	0%	-	0	0%	-
Operating Profit	21	17%	22	20%	-5%	15	13%	40%
Non-Operating Income	1	1%	4	4%	-75%	8	7%	-88%
Income Tax	(1)	-1%	(4)	-4%	-75%	(2)	-2%	-50%
Net Profit After Tax	21	17%	22	20%	-5%	21	18%	0%
Net Profit Attributable to Shareholders of the Parent	21	17%	22	20%	-5%	21	18%	0%
Basic EPS	0.31		0.31			0.3		

Q2 2021 Selected Items from Balance Sheet

(in TWD $ million)	Q2 2021 Amount	%	Q1 2021 Amount	%	Q4 2020 Amount	%
Cash & Cash Equivalent	209	21%	202	21%	210	22%
Account Receivables	116	11%	99	10%	95	10%
Inventories	98	10%	85	9%	87	9%
Net PP&E	461	45%	463	47%	470	49%
Total Assets	1,016	100%	977	100%	956	100%
Short-Term Debt	-	0%	-	0%	-	0%
Current Liabilities	104	10%	86	9%	87	9%
Total Liabilities	113	11%	95	10%	96	10%
Total Shareholders' Equity	903	89%	882	90%	860	90%

Q2 2021 Cash Flow Statement

(in TWD $ million)	Q2 2021 Amount	Q1 2020 Amount	Q2 2020 Amount
Beginning Balance	210	210	268
Cash from Ops.	32	22	(19)
Cash from Investing	(32)	(29)	109
Cash from Financing	(1)	(1)	(216)
Foreign Exchange Rate Adj.	0	0	0
Ending Balance	209	202	142
Free Cash Flow*	29	21	(25)

*** Free Cash Flow = Cash from operating activities - Capex**

Financial Summary

	2016 Amount	%	2017 Amount	%	2018 Amount	%	2019 Amount	%	2020 Amount	%	2021 H1 Amount	%
EPS	-0.18		0.23		0.82		0.87		0.91		0.62	
Dividend	-	-	0.1503	65.3%	0.6805	82.9%	0.78	89.6%	0.7307	80.3%	-	-
- Cash	-	-	0.1503	65.3%	0.6805	82.9%	0.78	89.6%	0.7307	80.3%	-	-
- Stock	-	-	-	-	-	-	-	-	-	-	-	-
Paid-In Capital ($M)	708		708		708		695		695		695	
ROE	-1.57%		1.98%		6.77%		7.06%		7.35%		4.76%	
ROA	-1.08%		1.43%		5.10%		5.18%		5.91%		4.36%	
Cash & Cash Equivalents ($M)	97		182		185		268		210		209	
Debt Ratio	28.8%		27.9%		25.8%		28.2%		10.1%		11.1%	
EBITDA/Revenue	3.3%		10.9%		20.3%		24.1%		24.1%		27.9%	

Strengthen Profitability Steady and Gradually




Q
A